The global cannabis use disorder treatment market is expected to grow from USD 1.65 billion in FY 2023, an increase from USD 1.57 billion in 2022, reflecting a year-over-year growth of over 5%. The market is forecasted to continue gaining momentum, exhibiting a compound annual growth rate (CAGR) of 4.9% throughout the forecast period from 2023 to 2033, ultimately reaching a valuation of USD 2.66 billion.
This growth is largely driven by increasing awareness and recognition of cannabis use disorder, as well as a growing need for effective treatment options. According to the United Nations Office on Drugs and Crime (UNODC), approximately 275 million people consumed drugs globally in 2020, with over 36 million suffering from drug use disorders, underscoring the critical need for effective interventions in this area.
As the demand for treatment options expands, stakeholders in the cannabis use disorder treatment market are likely to focus on developing comprehensive therapeutic approaches aimed at supporting individuals struggling with cannabis dependence.
Between 2010 and 2019, the number of people using drugs increased by 22%, owing in part to global population growth. Based on demographic changes alone, current projections suggest an 11% rise in the number of people who use drugs globally by 2030- and a marked increase of 40% in Africa, due to its rapidly growing young population. All these factors and statistics are prompting healthcare providers to invest in top-of-the-line treatments, therapeutics, and diagnostic procedures, paving way for significant market developments.
At present, cannabis use disorder is treated with counseling and therapy, though several medications are being investigated as potential alternatives. Experts opine that should a concrete drug be discovered; it may be combined with therapy to offer the best prognosis for patients. A CUD diagnosis can be complicated by comorbid or co-occurring mental health conditions. For instance, cannabis use disorder is strongly associated with both major depression and generalized anxiety disorder. Some studies have also found higher rates of cannabis use disorder in people with post-traumatic stress disorder.
Prominent treatment providers in the market are leveraging a host of therapeutic and combat approaches. These include an amalgamation of measures, such as conducting pipeline studies to develop effective drug candidates, offering therapy sessions in-house, or collaborating with healthcare tech providers to design apps aimed at helping reduce cannabis and opioid dependence in phased manners.
Competitive Landscape
While a majority of cannabis use disorder treatments are based on counseling and therapy, healthcare companies are conducting extensive clinical trials, implementing research & development projects, and collaborating with major funding agencies and other established market players. Some key players profiled in this report include Cipla Limited, Intas Pharmaceuticals Limited, Orexo AB, and Allergan plc. to name a few.
- Orexo AB is a prominent face in the cannabis use disorder treatment domain. Its amorphOX® drug delivery technology is highly scalable, possessing unique properties which support highly differentiated pharmaceutical products. One of its pipeline projects includes the OX124 medication for treating opioid overdose. Containing Naloxone as its API, the drug is expected to be launched in the US market by the 2nd half of 2023.
- In November 2022, Indivor Plc. entered into a definitive agreement with Opiant Pharmaceuticals Inc. wherein the former will acquire the latter so as to cement its position as a leader in addiction treatment. Through this acquisition, Indivor will now supervise the potential of OPNT003, an opioid overdose treatment drug that will reduce dependence on illicit drugs such as fentanyl. Fentanyl is responsible for over 100,000 deaths due to overdose across the USA
- BioCorRx Inc. announced a partnership with Government Plus LLC, a leading provider of private sector healthcare to veterans, for expanding its Beat Addiction Recovery Program. BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion.
Key Companies Profiled
- Cipla Limited
- Intas Pharmaceuticals Limited
- Orexo AB
- Allergan plc.
- Alkermes plc.
- Indivior plc.
- Noramco, Inc.
- Mallinckrodt Plc.
- BioCorRx Inc.
- Glenmark Pharmaceuticals Limited
- Dr. Reddy’s Laboratories
- Purdue Pharma L.P
Key Segments Profiled in the Cannabis Use Disorder Treatment Industry Analysis
By Type:
- Tobacco/Nicotine and Vaping
- Alcohol
- Marijuana
- Synthetic Cannabinoids
- Others
By Treatment:
- Detoxification
- Counselling & Behavioral Therapy
- Medication
- Support Group
By End User:
- Hospitals and Clinics
- Rehabilitation Centers
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
